Actelion thinks it can reach blockbuster heights with new pulmonary arterial hypertension (PAH) treatment Uptravi, approved by the FDA last month and launched earlier this week. And a price tag between $160,000 and $170,000 will certainly help it get there. Don't expect payers to balk at the lofty list price, though, the Swiss biotech's COO, Otto Schwarz, told analysts on a Tuesday call. Uptravi will come cheaper than rivals--including United Therapeutics' ($UTHR) Tyvaso--meaning that payers are unlikely to put up a fight. More from FiercePharma
> Allergan ($AGN) and Perrigo ($PRGO) have launched a store-brand version of Reckitt Benckiser's Mucinex D extended-release tablets. Release
> Teva ($TEVA) and Lupin have each launched a generic version of Johnson & Johnson's ($JNJ) oral contraceptive Ortho Tri-Cyclen Lo. Release | Release
> Teva and Takeda will shift Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes into a new company as part of their generics joint venture in Japan. More
> Roche ($RHHBY) and the U.K. Department of Health have begun trialing the Swiss drugmaker's RoActemra, an arthritis treatment, to see if it can be repurposed as a therapy for pulmonary arterial hypertension (PAH). Report
And Finally... The Wu-Tang Clan's de facto leader, RZA, says he doesn't regret selling the only copy of his group's latest album to indicted drug company exec Martin Shkreli. More